Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2017

View Archived Issues

Phase I study to compare safety and pharmacokinetics of NVP-1402 and NVP-1402R

Potent PI3Kdelta inhibitors for the treatment of inflammatory and autoimmune diseases

MicroQuin describes cancer candidates MQ-001 and MQ-002

RepliCel Life Sciences reports interim data from phase I study of RCS-01

FDA accepts for review sNDA seeking approval of ibrutinib in chronic GvHD

Bristol-Myers Squibb presents prodrug of BMT-1438 for the treatment of rheumatoid arthritis

DuPont announces business transaction agreement with FMC

Amgen seeks to expand current indication for Xgeva to include patients with multiple myeloma

BAY-1816032, a novel BUB1 inhibitor with potent antitumor activity

FDA grants priority review to sBLA for Opdivo in colorectal cancer

RedHill Biopharma's ABC-294640 receives FDA orphan drug designation for cholangiocarcinoma

Intralytix and BioPhage to develop topical bacteriophage treatment for S. aureus-infected wounds

Meiji Seika Pharma and Eisai sign licensing agreement for safinamide in Japan and Asia

Pharmacokinetics and pharmacodynamics of AG-B1512 in preclinical models reported

Evotec reaches first milestone in diabetes collaboration with Sanofi

Roche presents Toll-like receptor 8 agonists

Merck KGaA discloses ASIC1 inhibitors

QIAGEN obtains license to RNA biomarker from Johns Hopkins

Janssen Pharmaceuticals and collaborator divulge dengue virus replication inhibitors

BloodCenter of Wisconsin launches more precise VWF test in U.S.

Pharmascience discovers Tec family kinase inhibitors

AB Science identifies SYK kinase inhibitors

X4-136 in combination therapy with anti-PD-1 improves survival in murine ovarian cancer model

Phase I/II trial of a novel vaccine candidate AV-0328

NantKwest and Viracta Therapeutics close series B financing, enter partnership

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...